There is no single right way to source a cleansing oil. I have watched teams overpay for flexibility they never used, and I have watched teams lock into a cheap quote that cost them triple in rework. The right route depends on three things: your first order volume, whether you own the formula, and how soon you need stock on a shelf.

I am a procurement manager at a 40-person private-label skincare company. I have managed our formulation and packaging budget (roughly $1.2M annually) for four years, negotiated with 30+ vendors, and documented every order in our cost tracking system. Here is how I would break this down today.

The Three Routes (And Why the Distinction Matters)

Most sourcing advice treats cleansing oil as one category. It is not. A 3,000-unit first run and a 120,000-unit annual contract are different businesses. The vendors are different, the cost drivers are different, and the risks are different. The three routes I use:

  • Under 5,000 units: testing the water. You are buying market feedback, not a final formula.
  • 5,000–50,000 units: steady replenishment. You are buying a repeatable supply.
  • 50,000+ units annually: integration. You are managing a supply relationship, not a purchase order.

Pick the wrong route and you either pay too much for flexibility or lock yourself into a supply chain that cannot flex. Both mistakes are expensive, just in different ways.

Route 1: Under 5,000 Units — Buy Feedback, Not a Formula

For a first run under 5,000 units, the math favors stock formulas over custom development. Honestly, that sounds like giving up differentiation. But hear me out.

Custom formulation for a facial cleansing oil runs $3,000–8,000 in development alone (lab time, stability testing, iteration) before you have paid for a single unit. At 3,000 units, that is $1.00–2.70 per unit in amortized development cost — on a product that might wholesale for $6–9. That is a big chunk of your margin gone before the first bottle ships.

Stock centella light cleansing oil formulas are widely available from OEM suppliers. They are not identical, but the good ones are close enough for a first SKU. You are basically buying market feedback, not a final formula. The centella light category (lighter oil phase, faster rinse) is particularly well-served by stock options because it has become a standard entry point for brands testing the category.

The hidden cost to watch at this volume: small orders often exclude microbiological and stability testing from the quote. Ask explicitly. In our 2023 audit, we found that testing added 8–12% to small-batch landed cost when billed separately. A quote that looks 15% cheaper can flip to more expensive once testing, setup, and shipping are included (note to self: re-quote this every 6 months, suppliers keep changing their fee structures).

Route 2: 5,000–50,000 Units — Lock the Formula, Normalize the Active

Between 5,000 and 50,000 units, the game changes. You are no longer buying a test — you are buying a repeatable supply. This is where formula ownership starts to matter.

If you are using a supplier's stock formula, negotiate a formula lock clause. I have seen suppliers quietly change a carrier oil between batches because a raw material price spiked. The product still "meets spec" but the texture shifts. Your customers notice. We had a centella cleansing oil where the rinse feel changed between batch two and batch three — nothing technically wrong, but the reviews mentioned it. That cost us more in damage control than the formula lock would have.

Centella and ginseng are the two most common actives in this category, and they behave differently cost-wise. Centella extract (usually standardized to madecassoside content) is the bigger cost driver — going from 0.5% to 2% can add $0.40–0.90 per unit at 10,000 units depending on extract grade. Ginseng cleansing oil is often used at lower concentrations for positioning, so the cost delta is smaller, but the supply chain is less standardized. Ask for the extract specification, not just the percentage.

Here is where most buyers trip up: they compare per-unit quotes without normalizing active concentration. A $2.10 quote at 0.5% centella and a $2.60 quote at 2% are not comparable. The "cheaper" one may cost you more per unit of actual active. The question everyone asks is "what is your best price?" The question they should ask is "what is included in that price, and at what concentration?" (this was the single biggest change in how we evaluate quotes, circa 2024).

On the Ginza comparison — I get why people search for it. Ginza's cleansing oil is a retail benchmark, and it is natural to ask what the difference is between a Ginza-type product and a B2B-sourced one. The honest answer is that retail pricing and B2B sourcing cost structures do not map cleanly. A retail product's price includes brand, distribution, and retail margin that have nothing to do with formulation cost. You cannot reverse-engineer a sourcing budget from a shelf price. What you can do is benchmark texture and rinse behavior, then ask suppliers what formulation approach gets you there at your target cost. That is a more useful conversation than a price comparison.

Route 3: 50,000+ Units — Manage the Relationship, Not the Invoice

Above 50,000 units annually, you are not sourcing a product — you are managing a supply relationship. This is where total cost of ownership thinking pays off most, and where the cheapest quote is most likely to be a trap.

At this volume, the per-unit spread between vendors narrows to maybe 5–8%, but the cost of a stockout or a quality failure is enormous. We calculated that a two-week stockout on our best-selling facial cleansing oil SKU cost roughly $14,000 in lost sales and expedited replacement orders in Q2 2024. That single event wiped out the savings from three quarters of aggressive price negotiation.

Counterintuitive advice: do not squeeze the last 3–5% out of your primary supplier. I have seen procurement teams win a 4% price cut and lose priority scheduling when capacity tightened. In Q3 2024, during a busy season, our primary supplier prioritized accounts that had not beaten them down. We kept our 3% margin and got our orders on time. A competitor's buying team, who had pushed harder, waited an extra 11 days and paid for air freight. The 3% they saved disappeared in one shipment.

Dual sourcing is standard at this volume, but split it deliberately — 70/30, not 50/50. You want a clear primary so both suppliers know where they stand, and a qualified secondary who can scale if needed. The secondary should get enough volume to stay engaged and keep their pricing honest. A 70/30 split does both.

Which Route Are You Actually On?

Three questions place you quickly:

  1. What is your first order volume? Under 5,000 units, stock formula. Accept the per-unit premium. You are buying information.
  2. Do you own your formula? If yes, you are in Route 2 or 3 territory regardless of volume — the formula is the asset. If no, the supplier relationship is the asset, and formula lock clauses matter more than price.
  3. What is your timeline to shelf? Under 90 days pushes you toward stock formulas. Six months or more opens up custom development and lets you negotiate from a stronger position.

If you are unsure, start one route lower than you think you need. It is easier to graduate to a bigger commitment than to unwind one. I have never regretted starting small and scaling. I have regretted the opposite twice.

One caveat: this is based on our quotes and orders through Q4 2025. Raw material prices, MOQ policies, and lead times shift — the centella extract market in particular has been volatile. Verify current terms before you budget. I do not have hard data on how the whole industry splits across these three routes, but my sense from vendor conversations is that most first-time buyers overestimate how much customization they need at launch and underestimate how much supplier stability matters at scale. Those two mistakes pull in opposite directions, which is probably why sourcing cleasing oil well is harder than it looks.